Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis

Enrollment completed in placebo-controlled, randomized, dose-finding, multi-country, multi-center Phase II sepsis studyTopline Data Expected in late Q1 2024 Nes-Ziona, Israel, Dec. 20, 2023 ...

Related Keywords

United States ,Israel ,Eric Ribner ,Shachar Shlosberger ,Einat Galamidi ,Exchange Commission ,Enlivex Therapeutics Ltd ,Nasdaq ,Drug Administration ,Data Expected ,Medical Vice President ,Harbor Statement ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,